Conference on Congenital CMV Infection, Orvieto
A-07. Congenital cytomegalovirus infection and newborn hearing screening
A-09. Post traumatic transmission of cytomegalovirus(CMV) to the foetus and congenital CMV infection
A-11. Cytomegalovirus(CMV) B genotypes in Brazilian mothers and their congenitally infected infants
A-46. Expression of human cytomegalovirus immediate early genes disrupts normal development in a transgenic drosophila model
B-06. Congenital and perinatal CMV infection in urine and dried blood spots in Argentina
B-14. CMV congenital infection: results of a prospective study
B-16. A study of congenital and postnatal cytomegalovirus(CMV) infection in the neonatal unit at the Royal London Hospital, United Kingdom
B-17. Audit of a 10 year period(1995 to 2005) congenital CMV screening in the special care baby unit, Royal London hospital
B-18. Congenital CMV infection and sensorineural hearing loss: need of identification of asymptomatic newborns
B-19. Retrospective diagnosis of congenital cytomegalovirus infection using preserved umbilical cords
B-20. Retrospective diagnosis of congenital cytomegalovirus infection patients with sensorineural hearing loss using the perilymphatic fluid
B-24. Optimisation of retrospective diagnosis of cytomegalovirus congenital infection from dried blood spots
B-28. Maternal IgM negative antibodies coexisting with fetal ultrasound features of infection do not rule out a congenital CMV infection
B-29. Diagnostic relevance of sensitive assays for CMV IgM in pregnancy
B-30. Performance data of the newly developed completely automatized CMV IgG. IgM and avidity assays on the ARCHITECT platform
B-31. Development of a completely automated CMV avidity assay for the ARCHITECT instrument using a novel technology with direct detection of low avidity antibodies(AVICOMP)
B-32. Prospective evaluation of human cytomegalovirus (HCMV) detection in blood for diagnosis of primary and congenital HCMV infection
B-34. Diagnosis of congenital cytomegalovirus infection in dried blood spots: a 5 year experience in Portugal
B-38. Serology of CMV infection in fertile age women
B-41. Blood spot PCR detection of congenital CMV: linkage to newborn hearing screening
B-45. Prenatal diagnosis of cytomegalovirus infection
B-47. CMV primary infections in pregnant women in Friuli Venezia Giulia region
B-50. Epidemiological study of congenital CMV infection in newborns in Sweden
B-51. Measurement of CMV IgG avidity improves the diagnosis of congenital cytomegalovirus infection
B-54. Congenital cytomegalovirus infection: risk analysis via a neural analyzer
C-05. Outcome of 10 children with congenital CMV infection in paediatrics at Besancon hospital
C-15. Detection of cytomegalovirus (CMV) antibodies in urine and CMV congenital infection
C-35. Spontaneous improvement of fetal cytomegalovirus infection
C-39. Risk factors of post-natal symptomatic CMV infection in preterm infants
C-40. Neuroimaging findings and neurological outcome in symptomatic congenital cytomegalovirus infection
C-42. HCMV gN genotypes distribution among congenitally infected newborns monitored during a one-year follow-up
D-56. Comparative study of the immune response to cytomegalovirus in pregnant women and their congenitally infected neonates
E-27. Congenital cytomegalovirus infection: long-term outcome
E-33. Molecular epidemiology of human cytomegalovirus (HCMV) in families of pregnant women with primary HVMV infection
F-12. Congenital cytomegalovirus infection in preterm newborn: case report
F-13. Congenital cytomegalovirus infection:therapy and follow-up in newborns
F-52. Effects of ganciclovir therapy on selected hematological parameters in treatment of congenital cytomegalovirus infection in newborns
F-53. Long term treatment with oral Valganciclovir for congenital cytomegalovirus (CMV) infection
F-57. Congenital Cytomegalovirus (CMV) infection leading to neonatal cholestasis and response to ganciclovir
Oral and Poster Scientific Papers
The burden of congenital CMV disease
Congenital CMV infection, impaired placental development and compensation after immunotherapy
Model systems for studying congenital cytomegalovirus infection
A-10 Maternal viral excretion and neutralizing antibodies in congenital cytomegalovirus(CMV) infection in a highly seroimmune population
A-49, Human cytomegalovirus causes migration disturbances in human neural precursor cell cultures
Advances in the diagnosis of materno-fetal CMV infection
Diagnosis and management of fetal infection. A perinatologist perspective
B-01. Under-reporting of infant mortality caused by congenital cytomegalovirus infection
B-23. Epidemiology of materno-fetal CMV infections in France
Searching for prognostic markers of HCMV transmission and disease
Ethical dimensions of the fetus as a patient
C-36. Non-virological markers of infection and damage in human cytomegalovirus-infected fetuses
C-26. Are HCMV DNA loads in urine and blood of infected pregnant women prognostic markers of congenital infection in their newborns?
C-08. One year epidemiological study of CMV infection during pregnancy in a French hospital
C-48. Impact of confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive CMV-IgM titers
T cell development in human cytomegalovirus infection
Cellular immunity to CMV during foetal life
D-02. Development of human cytomegalovirus-specific T-cell-mediated immune response in pregnant women with primary infection
D-25. T lymphocyte response to congenital CMV infection
D-37. Functional virus-specific CDB' T cells but defective CD4' T cells in infants with congenital and postnatal CMV
D-21. Diversification of CMV-specific CDB' T cell responses over time following primary CMV infection in infants
Prevention of congenital CMV infection by serologic screening of pregnant women: a rational approach
E-22. Women's knowledge of congenital cytomegalovirus
E-55. Interventions to prevent congenital CMV infection? What can we learn from studies on Toxoplasma gondii?
E-44. Congenital CMV infection in HIV infected women on HAART
Animal Models for Evaluation of CMV Vaccine Strategies
Augmenting immunity to CMV with DNA vaccines
Strategies using attenuated poxviruses to confer protective immunity to CMV after transplant and potential role as a prophylactic vaccine for congenital infection
Therapy of congenital CMV infection
F-03. Ganciclovir therapy of congenital cytomegalovirus infection in symptomatic infants
F-43. Maternal administration of valacyclovir in symptomatic intrauterine cytomegalovirus infection
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.